Moreover, the 36-month beta value for VRNA is 0.39. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 59.93M and currently, short sellers hold a 10.12% of that float. On May 10, 2024, VRNA’s average trading volume was 445.89K shares.
VRNA) stock’s latest price update
The stock of Verona Pharma Plc ADR (NASDAQ: VRNA) has decreased by -0.87 when compared to last closing price of 14.88. Despite this, the company has experienced a -6.35% fall in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-09 that Verona Pharma plc (NASDAQ:VRNA ) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants David Zaccardelli – President, CEO & Executive Director Mark Hahn – Chief Financial Officer Christopher Martin – Chief Commercial Officer Tara Rheault – Chief Development Officer Conference Call Participants Andrew Tsai – Jefferies Tom Shrader – BTIG Ram Selvaraju – H.C. Wainwright Operator Hello, and welcome to Verona Pharma’s First Quarter 2024 Financial Results and Operating Highlights Conference Call.
VRNA’s Market Performance
Verona Pharma Plc ADR (VRNA) has experienced a -6.35% fall in stock performance for the past week, with a -9.34% drop in the past month, and a -9.40% drop in the past quarter. The volatility ratio for the week is 3.95%, and the volatility levels for the past 30 days are at 3.56% for VRNA. The simple moving average for the last 20 days is -5.42% for VRNA stock, with a simple moving average of -11.39% for the last 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Jefferies repeating the rating for VRNA by listing it as a “Buy.” The predicted price for VRNA in the upcoming period, according to Jefferies is $38 based on the research report published on May 22, 2023 of the previous year 2023.
Wedbush, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $27. The rating they have provided for VRNA stocks is “Outperform” according to the report published on September 19th, 2022.
Piper Sandler gave a rating of “Overweight” to VRNA, setting the target price at $31 in the report published on August 26th of the previous year.
VRNA Trading at -8.21% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.05% of loss for the given period.
Volatility was left at 3.56%, however, over the last 30 days, the volatility rate increased by 3.95%, as shares sank -8.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.54% lower at present.
During the last 5 trading sessions, VRNA fell by -6.35%, which changed the moving average for the period of 200-days by -25.73% in comparison to the 20-day moving average, which settled at $15.52. In addition, Verona Pharma Plc ADR saw -25.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from Rickard Kathleen A., who sale 36,248 shares at the price of $1.96 back on May 03 ’24. After this action, Rickard Kathleen A. now owns 2,621,552 shares of Verona Pharma Plc ADR, valued at $71,032 using the latest closing price.
Rickard Kathleen A., the Chief Medical Officer of Verona Pharma Plc ADR, sale 36,248 shares at $2.22 during a trade that took place back on Feb 05 ’24, which means that Rickard Kathleen A. is holding 2,731,624 shares at $80,503 based on the most recent closing price.
Stock Fundamentals for VRNA
The total capital return value is set at -0.22. Equity return is now at value -22.76, with -19.23 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -52.49.
Currently, EBITDA for the company is -67.15 million with net debt to EBITDA at 3.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 33.33.
Conclusion
To wrap up, the performance of Verona Pharma Plc ADR (VRNA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
